PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
about
[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.Phosphodiesterase type 5 and cancers: progress and challenges.Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.The mechanism of attenuation of epithelial-mesenchymal transition by a phosphodiesterase 5 inhibitor via renal klotho expression.Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma.[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
P2860
Q38622540-051FB52C-D6AC-4E68-94EA-ECAE99DEEB19Q38721255-4F66B528-751C-409F-8237-8A2CEE1558C3Q45073629-38819DED-4728-45E0-A8FC-D399D92C0677Q46238888-74F74BE7-AF60-4084-95D0-454E3C72A614Q47171803-4CFF9BD5-D6B6-4D0E-B720-A554A2C4AB96Q47738152-9376AA19-7FA6-4EA9-A615-7B8472234E96Q47844871-F5DBD959-C4DA-4A81-A033-1EDB34190B21Q48239512-C4CC5D0D-7EC1-4452-8BA2-89DC9D3902CCQ49787645-19984B40-44CE-4045-895B-EFF41DCAA1EAQ50187396-48B85ACE-67EC-40F1-9ACE-773C1EDC5701Q55247585-50226438-5652-40DD-8B0F-DD44C69CF922
P2860
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@en
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@nl
type
label
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@en
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@nl
prefLabel
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@en
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@nl
P2093
P2860
P356
P1433
P1476
PDE5 inhibitors enhance the le ...... of cyclic GMP and nitric oxide
@en
P2093
Andrew Poklepovic
Jane L Roberts
Laurence Booth
Sarah Gordon
P2860
P304
P356
10.18632/ONCOTARGET.13640
P407
P50
P577
2016-11-26T00:00:00Z